The AGITG Innovation Fund is made possible through generous contributions from the Spencer Gibson Foundation, the His Honour Alan Bishop Fund and with donations raised through the GI Cancer Institute’s Gutsy Challenge.
AGITG members can apply for up to $200,000 to support a new AGITG pilot trial.
“The AGITG Innovation Fund is an important step in the process to develop new clinical trials for the AGITG,” commented Professor Tim Price, Chair of the AGITG/GI Cancer Institute. “The Fund awards protocols that will build on our research programs and enables AGITG members to accumulate the data required to approach funding bodies for a larger scale clinical trial.”
Contact Nina Ackerman to register your interest and request an application form: click here.
Applications will close on 26th July 2017 at 5:00PM AEST.
In 2016 the Innovation Fund was awarded to the new AGITG MONARCC pilot trial:
A randomised phase 2 study of panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer.
“Winning this award means a huge amount to me. The recognition of the importance of this research question from the AGITG is particularly gratifying,” said Dr Matthew Burge, Royal Brisbane and Women’s Hospital. “I now plan to lead a national study which I hope will improve the treatment options and outcome for elderly patients with advanced colorectal cancer.”
Eligible projects must be:
- Led by registered clinical members of the AGITG. At least one of the applicants listed on the application form must be a current registered member with a minimum of twelve months membership.
- Consistent with the scope and strategic direction of the AGITG research program (locally and internationally).
- Scientifically valid and of high quality with the potential to impact future clinical practice.
- Significant and/or innovative research.
- Feasible within the proposed time frame.
- Able to be linked to future AGITG grant applications or other funding opportunities if required.
- Expected to build capacity and/or collaborations for the AGITG.
Priority will be given to projects that:
- Are a pilot phase of a planned AGITG clinical trial or research project
- Are clinical or translational in nature
- Are conducted at Participating Institutions of the AGITG
- Build research capacity for the AGITG
- Provide educational opportunity for young AGITG researchers
- Have the potential to improve clinical practice standards
- Have the potential to reduce treatment burden on patients and funding systems (and may therefore be unlikely to attract commercial sponsors)
- Demonstrate collaboration between members and Participating Institutions of the AGITG.
It is recommended that research funding applications have a minimum of two (2) current AGITG Trial Principal Investigators from different AGITG Participating Institutions, and that large-scale project funding applications have a minimum of three (3) current AGITG Trial Principal Investigators from different AGITG Participating Institutions. Principal Investigators should include a mix of AGITG Investigators with a strong track record (relevant to success of future grants) and younger Investigators who will benefit from mentoring opportunities.